Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension
- PMID: 15864120
- DOI: 10.1097/01213011-200501000-00002
Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension
Abstract
CYP2J2 and CYP2C8 metabolize arachidonic acid (AA) to cis-epoxyeicosatrienoic acids (EETs), which play a central role in regulating renal tubular fluid-electrolyte transport and vascular tone. We hypothesized that functionally relevant polymorphisms in the CYP2J2 or CYP2C8 genes influence hypertension risk. We examined associations between CYP2J2*7 (G-50 T promoter) and CYP2C8*3 (Arg139Lys and Lys399Arg, which are in 100% linkage disequilibrium) polymorphisms and hypertension in a biethnic population from Tennessee. CYP2J2*7 variant allele frequency was significantly higher in African-Americans versus Caucasians (14.1% versus 7.7%, P=0.01), irrespective of hypertension status. When analysed separately by race, the genotype distribution of the CYP2J2*7 variant allele was not significantly different among African-Americans with/without hypertension, but was significantly different among Caucasians with/without hypertension (P=0.03). Indeed, the odds ratio of having hypertension attributable to carrying the CYP2J2*7 variant allele adjusted for age, gender, body mass index and family history was 0.39 (95% confidence interval 0.17-0.89) among Caucasians, suggesting a protective effect. Additional subgroup analyses revealed a significantly lower CYP2J2*7 variant allele frequency in hypertensive versus normotensive Caucasian males (5.6% versus 12.5%, P=0.02) and in hypertensive versus normotensive Caucasians without a family history of hypertension (1.5% versus 11.0%, P=0.03). With respect to the CYP2C8*3 variant, genotype distribution and allele frequencies were similar between normotensive and hypertensive subjects. This study provides evidence for an association between CYP2J2*7 genotype and hypertension in Caucasian males and Caucasians without a family history of hypertension, but suggests no association between CYP2C8*3 genotype and hypertension. Confirmation of these findings in additional populations is warranted.
Similar articles
-
CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.Pharmacogenet Genomics. 2007 May;17(5):349-58. doi: 10.1097/FPC.0b013e32809913ea. Pharmacogenet Genomics. 2007. PMID: 17429317 Free PMC article.
-
The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.Am J Hypertens. 2005 Oct;18(10):1276-81. doi: 10.1016/j.amjhyper.2005.04.019. Am J Hypertens. 2005. PMID: 16202848
-
Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population.Pharmacol Rep. 2015 Feb;67(1):97-101. doi: 10.1016/j.pharep.2014.08.010. Epub 2014 Sep 11. Pharmacol Rep. 2015. PMID: 25560582
-
Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk.Pharmacogenomics. 2007 Oct;8(10):1369-83. doi: 10.2217/14622416.8.10.1369. Pharmacogenomics. 2007. PMID: 17979511 Review.
-
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.Mol Diagn Ther. 2006;10(1):29-40. doi: 10.1007/BF03256440. Mol Diagn Ther. 2006. PMID: 16646575 Review.
Cited by
-
Cyp2j5-Gene Deletion Affects on Acetylcholine and Adenosine-Induced Relaxation in Mice: Role of Angiotensin-II and CYP-Epoxygenase Inhibitor.Front Pharmacol. 2020 Feb 5;11:27. doi: 10.3389/fphar.2020.00027. eCollection 2020. Front Pharmacol. 2020. PMID: 32116704 Free PMC article.
-
Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide.J Pharmacol Exp Ther. 2010 Sep 1;334(3):784-94. doi: 10.1124/jpet.110.167510. Epub 2010 May 25. J Pharmacol Exp Ther. 2010. PMID: 20501636 Free PMC article.
-
Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.FASEB J. 2013 Aug;27(8):2946-56. doi: 10.1096/fj.12-218040. Epub 2013 Apr 19. FASEB J. 2013. PMID: 23603837 Free PMC article.
-
CYP2C8 and antimalaria drug efficacy.Pharmacogenomics. 2007 Feb;8(2):187-98. doi: 10.2217/14622416.8.2.187. Pharmacogenomics. 2007. PMID: 17286541 Free PMC article. Review.
-
Genetic polymorphisms of the drug-metabolizing enzyme CYP2J2 in a Tibetan population.Medicine (Baltimore). 2018 Oct;97(40):e12579. doi: 10.1097/MD.0000000000012579. Medicine (Baltimore). 2018. PMID: 30290621 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical